Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure. [electronic resource]
Producer: 20081103Description: S346-9 p. digitalISSN:- 1533-4023
- Aldosterone -- blood
- Angiotensin-Converting Enzyme Inhibitors -- pharmacology
- Animals
- Bradykinin -- metabolism
- Bradykinin B2 Receptor Antagonists
- Collagen -- genetics
- Disease Models, Animal
- Dogs
- Enalapril -- pharmacology
- Endothelin-1 -- genetics
- Fibrosis
- Heart Failure -- drug therapy
- Hemodynamics -- drug effects
- Myocardium -- enzymology
- Nitric Oxide -- metabolism
- Nitric Oxide Synthase Type II -- metabolism
- Nitric Oxide Synthase Type III
- Quinolines -- pharmacology
- RNA, Messenger -- metabolism
- Receptor, Bradykinin B2 -- metabolism
- Renin -- blood
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.